homesitemapcontact us






Events and Presentations


Press Releases


SEC Filings


Stock Information


Analyst Coverage




Corporate Governance


Investor FAQs


Annual Reports, Proxy Statements, and Supplemental Financial Info


Email Alerts


For investor inquiries, please contact:

Investor Contact:
Scott Youngstrom



EnteroMedics® Inc. (NASDAQ: ETRM) has developed a novel medical device with the potential to advance weight loss treatment and address the growing global health crises associated with obesity and its co-morbidities, such as diabetes and hypertension. EnteroMedics is committed to advancing the scientific, medical and commercial potential of VBLOC® vagal blocking therapy, the Company’s proprietary neuroblocking technology, to benefit patients, health care providers and stakeholders around the world.

EnteroMedics was incorporated in Minnesota in December 2002 under the name Beta Medical, Inc. In 2003, the Company changed its name to EnteroMedics Inc. and in 2004 reincorporated in Delaware. EnteroMedics began trading on the NASDAQ Stock Market on November 15, 2007 and continues to be traded on the NASDAQ today under the ticker symbol ETRM.

EnteroMedics Inc. (NASDAQ: ETRM) 4:15 PM ET on Sep 20, 2017
Last Price Change Open Day High 52-Week High
0.01  down   (0.541%) 1.85 1.86 30.41
Volume Previous Close Day Low 52-Week Low
171,770 1.85 1.82 1.72

View all »Events & Presentations

Sep 26, 2017 at 11:00 AM ET
Ladenburg Thalmann 2017 Healthcare Conference

View all »Recent Releases

Sep 12, 2017
EnteroMedics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Sep 5, 2017
EnteroMedics Begins Post-Approval Study for the Treatment of Obesity with vBloc Therapy

Forward looking statement

This website contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial sales experience with our Maestro® Rechargeable System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and vBloc® Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 28, 2016. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.